Anti-RANKL therapy - Implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2075-2077

  Westenfeld, Ralf ^a   Ketteler, Markus ^a   Brandenburg, Vincent M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Chronic kidney disease; Osteoporosis; Osteoprotegerin; RANKL; Vascular calcification

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; DENOSUMAB; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ADYNAMIC BONE DISEASE; ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEFECT; BONE DEMINERALIZATION; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PATIENT CARE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY MECHANISM; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

EID: 33748079121     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl245     Document Type: Article

References (24)

1. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342
3. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-1057
4. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
5. Min H, Morony S, Sarosi I et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-474
6. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616
7. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000; 20: 1926-1931
8. McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-831
9. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1922-1928
10. Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014-3018
11. Ketteler M, Wanner C, Metzger T et al. Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int 2003; [Suppl]: S84-S87
12. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166-174
13. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire? Nephrol Dial Transplant 2004; 19 [Suppl 1]: I9-i13
14. Padagas J, Colloton M, Shalhoub V et al. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 2006; 78: 35-44
15. Torregrosa JV, Moreno A, Mas M, Ybarra J, Fuster D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int 2003; [Suppl]: S88-S90
16. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121
17. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676
18. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
19. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39: 580-586
20. Coen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238
21. Schoppet M, Al Fakhri N, Franke FE et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-4112
22. Nitta K, Akiba T, Uchida K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889
23. Morena M, Terrier N, Jaussent I et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270
24. Hruska KA, Saab G, Chaudhary LR et al. Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 2004; 24: 25-38